These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

872 related items for PubMed ID: 12894384

  • 1. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J.
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [Abstract] [Full Text] [Related]

  • 2. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B, Phillips LH, Juel VC.
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [Abstract] [Full Text] [Related]

  • 3. Myasthenia gravis and myasthenic syndrome.
    Antozzi C.
    Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
    [Abstract] [Full Text] [Related]

  • 4. Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
    Sha SJ, Layzer RB.
    Muscle Nerve; 2007 Jul; 36(1):115-7. PubMed ID: 17206662
    [Abstract] [Full Text] [Related]

  • 5. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Nicolle MW.
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1978-2005. PubMed ID: 27922503
    [Abstract] [Full Text] [Related]

  • 6. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I.
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [Abstract] [Full Text] [Related]

  • 7. Lambert-Eaton myasthenic syndrome in childhood.
    Kostera-Pruszczyk A, Ryniewicz B, Rowinska-Marcinska K, Dutkiewicz M, Kamińska A.
    Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
    [Abstract] [Full Text] [Related]

  • 8. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Bodkin C, Pascuzzi RM.
    Neurol Clin; 2021 Feb; 39(1):133-146. PubMed ID: 33223079
    [Abstract] [Full Text] [Related]

  • 9. Treatment in Lambert-Eaton myasthenic syndrome.
    Maddison P.
    Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
    [Abstract] [Full Text] [Related]

  • 10. A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure.
    Roohi F, Smith PR, Bergman M, Baig MA, Sclar G.
    Neurologist; 2006 Nov; 12(6):322-6. PubMed ID: 17122730
    [Abstract] [Full Text] [Related]

  • 11. [The pathophysiology and treatment of autoimmune neuromuscular junction diseases].
    Motomura M.
    Rinsho Shinkeigaku; 2011 Nov; 51(11):872-6. PubMed ID: 22277398
    [Abstract] [Full Text] [Related]

  • 12. [Therapy of myasthenia gravis].
    Rilling G, Tettenborn B.
    Praxis (Bern 1994); 2001 Aug 16; 90(33):1350-4. PubMed ID: 11534319
    [Abstract] [Full Text] [Related]

  • 13. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases.
    Lorenzoni PJ, Scola RH, Kay CS, Parolin SF, Werneck LC.
    Arq Neuropsiquiatr; 2010 Dec 16; 68(6):849-54. PubMed ID: 21243240
    [Abstract] [Full Text] [Related]

  • 14. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A, Turbeville S, Lounsbury D.
    Curr Med Res Opin; 2010 Jun 16; 26(6):1363-75. PubMed ID: 20377318
    [Abstract] [Full Text] [Related]

  • 15. [Proximal muscle weakness, depressed tendon reflexes and autonomic dysfunction: the Lambert-Eaton myasthenic syndrome].
    Wirtz PW, Kuks JB, Wintzen AR, Verschuuren JJ.
    Ned Tijdschr Geneeskd; 2001 Jan 13; 145(2):57-61. PubMed ID: 11225256
    [Abstract] [Full Text] [Related]

  • 16. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW.
    Eur J Neurol; 2006 Jul 13; 13(7):691-9. PubMed ID: 16834699
    [Abstract] [Full Text] [Related]

  • 17. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
    International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ.
    J Neurol Sci; 2020 May 15; 412():116803. PubMed ID: 32247193
    [No Abstract] [Full Text] [Related]

  • 18. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis.
    Baslo MB, Deymeer F, Serdaroglu P, Parman Y, Ozdemir C, Cuttini M.
    Neuromuscul Disord; 2006 Jul 15; 16(7):454-8. PubMed ID: 16806929
    [Abstract] [Full Text] [Related]

  • 19. Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J.
    Rev Neurol (Paris); 2004 Feb 15; 160(2):177-80. PubMed ID: 15034474
    [Abstract] [Full Text] [Related]

  • 20. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.
    Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, Wintzen AR, Verschuuren JJ, Dutch Myasthenia Study Group.
    J Neurol; 2003 Jun 15; 250(6):698-701. PubMed ID: 12796832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.